Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in CSU Patients
Celldex Therapeutics, Inc. is starting its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The studies will also include patients who remain symptomatic after treatment with […]